Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press coverage
pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
Press coverage
Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
Press coverage
Drug Target Review — Combining autotaxin and TGF-β inhibitors in cancer
Press release
iOnctura to present research on roginolisib and IOA-359 at ASH
Press coverage
Labiotech — Could this be the start of a new era for PI3K drugs?
Press release
iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press release
New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Data & publication
Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma
Press coverage
Drug Discovery World — Meet the researcher: Giusy Di Conza
Data & publication
Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib
Press coverage
pharmaphorum — Realising the potential of autotaxin inhibition in cancer
Data & publication
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
Looking for media
resources?